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Abstract
Adherence to treatment for hepatitis C virus (HCV) maximizes treatment efficacy. Missed doses
and failing to persist on treatment are two patient-level processes that are rarely defined or
analyzed separately from other factors affecting treatment adherence. We evaluated the prevalence
and patterns of missed doses and nonpersistence, and identified patient characteristics associated
with these outcomes. Missed doses of ribavirin (RBV) and peginterferon (PEG), measured
prospectively in Virahep-C using electronic monitoring technology, were analyzed using
generalized estimating equations. Cox proportional hazards models analyzed time to
nonpersistence from baseline to week 24 (N=401) and from week 24–48 in Responders (N=242).
Average proportion of PEG and RBV missed doses increased over time from 5 to 15% and 7 to
27%, respectively. Patients who were younger, African American, unemployed, or unmarried
were at greater risk of missing PEG from week 0–24; higher baseline depression predicted missing
PEG from weeks 24–48. Patients who were younger or African American were more likely to
miss daily RBV from weeks 0–24; and those without private insurance or employment were more
likely to miss RBV from weeks 24–48. Fifty-two patients failed to persist on treatment for patient-
driven deviations. Predictors of nonpersistence from weeks 0–24 included younger age, lower
education, public or no insurance, or worse baseline headaches. In conclusion electronic
monitoring and the prospective Virahep-C design afforded a unique opportunity to evaluate
missing doses and nonpersistence separately, and identify patients at risk for nonadherence. These
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processes will be important to investigate as the dosing schedules of antiviral regimens become
increasingly complex.
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Nonadherence to prescribed treatment regimens for hepatitis C viral (HCV) infection has
been a major impediment to treatment success during peginterferon and ribavirin (PEG/
RBV) regimens (1, 2). Treatment effectiveness of the new triple therapy regimens will
continue to be hindered by nonadherence given the greater complexity of the daily dosing
schedules, requisite nutritional intake, and additional side effects of the protease inhibitors
(3). “Adherence to the prescribed treatment protocol” as it has been described in the HCV
literature, usually refers to: 1) a combination of the proportion of actual doses taken
compared to the total amount of prescribed doses with 2) the proportion of actual days on
treatment compared to the ideal prescribed treatment duration. Patients who are maintained
on greater than 80% of PEG and 80% of RBV for 80% of the treatment duration (the
80/80/80 standard) have greater chances of achieving a sustained virological response (SVR)
(1, 4).
Nonadherence to the prescribed regimens occurs for myriad reasons including premature
treatment discontinuations, dose reductions, and patients missed doses that are not well
differentiated in the literature because these deviations from the protocol are often combined
into one overall composite “treatment adherence” variable. Unfortunately, composite
adherence variables (e.g., the 80/80/80 standard) obscure our ability to distinguish
medically-necessary protocol deviations from patient-driven deviations. Importantly, the
latter may be modified through interventions, thereby increasing the number of patients who
can be treated successfully.
Two patient-driven protocol deviations that are useful to define and measure individually are
“execution of dosing” and “persistence” (5–7). Execution of dosingoften referred to as
“medication adherence,” is defined as the extent to which a patient acts in accordance with
the prescribed interval and dose of a dosing regimen (5). Poor execution of dosing is often
termed “missed doses.” While execution of dosing is infrequently measured among patients
with HCV, studies indicate that patients report problems taking their HCV medications and
that inadequate dosing may impede virologic response and SVR (2, 8–13). To date, there is
a lack of understanding as to why patients miss taking their medications as prescribed.
In contrast, medication persistence is defined as the total length of time a patient takes a
medication, from first dose to last dose(5, 7). In the broader medication adherence literature
which seeks to understand and improve patient’s medication-taking behavior and
emphasizes patient adherence “nonpersistence” generally refers to all behaviors or decisions
to stop a medication regimen early which are judged to be under the patient’s control. In
these settings, examples of nonpersistence include, but are not limited to, intolerance of
unpleasant but not medically dangerous side effects, not refilling prescriptions, being lost to
follow-up, and noncompliance with physician recommendations (5–7). Typically,
medically-necessary or physician-recommended deviations from medication regimens are
not described in medication adherence studies, not because they do not occur, but because
these deviations are not considered “patient adherence” issues(14). The field of HCV has
historically used the term “premature treatment discontinuation” to capture all reasons for
premature discontinuation, without making any distinction between patient-driven
nonpersistence and medically-necessary provider-driven discontinuations, both of which can
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occur during HCV treatment(15). Since both patient-driven and medically-necessary
discontinuations occur during HCV treatment but will ultimately require different types of
interventions, it is prudent for the field to disentangle these processes(15). While this
differentiation is not well-described in the HCV literature, adoption of such lexicon would
promote a more fine-grained analysis and understanding of these interrelated but distinct
phenomena which would better serve intervention development to target precise issues that
jeopardize treatment success. Also, aligning the HCV adherence literature with the broader
adherence literature would help to inform our conceptualization and understanding of these
distinct processes, and vice versa contribute to the larger empirical literature on adherence.
A better understanding of these phenomena and adoption of such definitions would allow
researchers: 1) to apply a consistent lexicon for future HCV adherence research; 2) identify
the largest threats to HCV treatment efficacy; 3) to develop precise interventions to address
each type of protocol deviation (e.g., behavioral reminder systems for missed doses; side
effect management for nonpersistence); and 4) to identify subgroups of patients in need of
further monitoring and intervention.
The objective of the current study was to examine the prevalence and patterns of the missed
doses and nonpersistence (i.e, patient-driven treatment discontinuations), and to identify
patient characteristics associated with these two patient-driven protocol deviations. The
specific aims were as follows: 1) To prospectively examine the proportion of patients who
missed doses of weekly PEG and daily RBV and failed to persist on PEG/RBV treatment;
and 2) To identify patient characteristics associated with missed doses and nonpersistence.
MATERIALS AND METHODS
Virahep-C Design
We used data from the NIDDK-funded Virahep-C study, which stratified sampling to enroll
196 African American (AA) and 205 Caucasian American (CA) adults with chronic
hepatitis C, genotype 1 infection at eight U.S. medical centers to study factors associated
with differential response to antiviral therapy between racial groups (12). In brief, the results
of the main study demonstrated SVR rates of 28% in AAs compared to 52% in CAs, racial
differences in viral response were found early as early as treatment week 4, and these
differences were not explained by disease characteristics, baseline viral load, or amount of
drug taken. One of the specific aims of Virahep-C was to evaluate pre-treatment and on-
treatment factors that may account for differential treatment responses, therefore adherence
to the treatment protocol was rigorously measured as a potential predictive variable.
Participants were treated with PEG/RBV for a minimum of 24 weeks. Those with detectable
viremia at week 24 (i.e.“Nonresponders”) were discontinued from therapy, whereas patients
with undetectable or indeterminate HCV RNA by 24 weeks were continued for 48 weeks
(“TW24 Responders”). Patients attended a baseline visit and then follow-ups at treatment
weeks 2, 4, 8, 12 and then monthly up to 48 weeks. SVR was defined as undetectable
viremia (HCV RNA < 50 IU/mL) 24 weeks after stopping therapy.
Virahep-C Patient Education and Adherence Program
To optimize treatment efficacy, all participants received numerous adherence-enhancing
interventions throughout the study, including a modified version of the Medication
Adherence Training Interview (16), informational-exchange, skills development, social
support enlistment, and educational videos. Details of the Virahep-C protocol can be found
at https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#VIRAHEP-C.
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Baseline Sociodemographic and Clinical Characteristics—Baseline data were
collected via self-report and medical chart reviews. Sociodemographic variables included:
age, gender, race, marital status, education level, employment status, and health insurance
status. Medical variables included: fibrosis level, smoking status, alcohol consumption,
number of medications taken for comorbid conditions, source of HCV infection, and
presence of baseline antidepressant use.
Baseline Psychosocial Instruments
Depressive Symptoms: The Center for Epidemiologic Studies-Depression (CES-D) scale
was used to measure depressive symptoms (17). The CES-D total score ranges from 0 to 63,
with higher scores indicative of more severe symptomatology.
Visual Analog Symptom Scales: Six visual analog scales (VASs) were used to assess: (1)
overall symptomatology (VAS-ALL), (2) fatigue (VAS-FAT), (3) headaches (VAS-HEAD),
(4) muscle/joint aches and pains (VAS-ACHE), (5) irritability (VAS-IRRIT), and (6)
depression (VAS-DEP). Participants marked a computerized line via a touch screen
computer which was converted to a continuous 0 (“none”) to 10 (“worst ever”), with higher
scores indicative of worse symptoms in the week preceding a clinic visit.
Health-Related Quality of Life: The SF-36 Health Survey was used to measure health-
related quality of life, and yields a mental composite score (MCS) and physical composite
score (PCS) (18).
Social support: Social support were assessed using the MOS Social Support Survey (19).
The overall social support score, calculated as a continuous variable, ranged from 0–100%
with higher scores indicative of more social support.
Outcome Measures
Execution of PEG and RBV Dosing: Dosing of weekly PEG and daily RBV was measured
by the Medication Event Management System (MEMS). MEMS uses a computer chip in the
cap of a medication vial that records the precise date and time the vial was opened, and
presumably, when the drug was taken. Study participants were instructed in proper use of
the MEMs caps before and during each clinic visit. MEMS caps provide a highly accurate,
reliable and objective measure of drug-taking behavior when used correctly(20). A MEMS
cap was placed on the RBV vial and five PEG syringes were placed inside a large opaque
prescription bottle that accommodated the MEMS cap. MEMs data from computer chips
were downloaded at each study visit.
Using the MEMs data, execution of dosing was defined as the number of prescribed doses
actually taken weekly for PEG (0,1) and daily for RBV (0,1,2). Patients were expected to
inject PEG once every 7 days; for these analyses, PEG needed to occur 6–8 days from the
previous PEG dose to be coded as 1 (i.e. “adherent). Participants were expected to ingest the
prescribed dose of RBV twice within a 24 hour window; for these analyses, RBV dosing had
to occur twice within each 24-hour period (3a.m. to 3a.m.) to be coded as 2 (i.e. “fully
adherent”) or once in 24 hours to be coded as 1 (i.e. “partially adherent”) for that day. If a
subject failed to open the MEMs cap during these prespecified windows, they were coded as
0 (i.e. nonadherent). When a subject was instructed to dose reduce to 0 for either PEG or
RBV, and did not open the MEMS cap during this time, s/he was considered fully adherent.
Time 0 (first day/opening) was excluded for all subjects because this generally occurred
during training in MEMS cap use.
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Reasons for Missed Doses: If patients endorsed missing any of their medications in the 4
weeks preceding a study visit, they were administered an adapted 14-item Barriers to
Adherence questionnaire (21, 22). For each reason, patients indicated how often they missed
taking their study medications on a 4-point Likert scale (Never, Rarely, Sometimes, Often).
Nonpersistence: Nonpersistence was defined as time to patient-driven premature study or
medication discontinuation at any time during the study, excluding nonresponse.
Nonpersistent events included: drop out; intolerance to side effects; patient preference;
nonadherence to study protocol; patient withdrawal; loss to follow-up or refusal. Serious
adverse events and deaths were censored events since these were considered out of the
patients’ control. For the 0–24 week analyses, all patients who persisted to week 24 were
censored at day 168. For TW24 Responders, the clock was reset to 0, and nonpersistence
was analyzed from week 25 to 48.
Analytic and Statistical Plan—Dosing execution was summarized weekly for RBV and
in 4 week blocks for PEG by calculating the proportion of doses taken (number of doses
actually taken divided by the expected number of doses to be taken). Data are presented
along with 95% confidence intervals. Proportions and frequencies are used to describe
reasons for missed doses and nonpersistence over the 48 week treatment period. We
employed generalized estimating equations to model poor execution of dosing (“missed
doses”) over time using type 3 score statistics to calculate p-values. The multinomial
distribution with the cumlogit link function was used for daily RBV to model the
probabilities of levels of n having lower order values (i.e. comparison of fully adherent, n=2,
to partially adherent or nonadherent (n=1 and 0), and partially adherent (n=1) compared to
nonadherent (n=0)). The logit link function was used for weekly PEG. We explored the
bivariate association between execution of dosing and each of the baseline
sociodemographic, clinical and psychosocial characteristics. Any relationships significant at
the 0.20 level were included in a multivariate model. To avoid potential multicollinearity
issues, the VAS-ALL and VAS-DEP were excluded from the initial multivariate model due
to moderate to strong correlations with other VASs and baseline CES-D, respectively.
Effects significant in the multivariate model at the 0.05 level after backwards selection were
retained in the final model. Models were run on the full sample (N=401) for treatment week
0 to 24. Conditional on being a TW24 Responder and continuing on treatment, models were
repeated for weeks 24 to 48 (N=242). Baseline CES-D was excluded from the initial
multivariate model due to its high correlation with VAS-DEP and its bivariate association
with missing PEG doses not being as strong.
Patient-driven nonpersistence: was analyzed as time to event data. Kaplan Meier curves
were used to plot the raw data. Cox proportional hazards models were used to explore
variables associated with nonpersistence: (1) from baseline to week 24; and (2) conditional
on being a TW24 Responder, from week 24–48, with the clock reset to time 0.
Characteristics significant at the 0.20 level were included in multivariate models. Variables
significant at the 0.05 level after backwards selection were retained in the final model.
Owing to lack of power due to a small number of nonpersistent events from weeks 24–48,




Patient characteristics for the 401 Virahep-C participants are described elsewhere (12). The
panel in Figure 1 shows the average proportions of missed doses plotted over the course of
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the 48 week treatment period, in 4 week blocks for PEG (Figure 1A) and weekly for RBV
(Figure 1B). The proportion of missed doses of PEG at each week was low, remaining
below 10% throughout the study, with the exception of the last month. In contrast, there was
a steady increase in missing doses of RBV over time, with approximately 15% of doses
missed by patients at week 24, and 25% of doses missed by week 48.
For those who reported missing doses, the most common reasons endorsed by more than
20% of respondents at any time point included: feeling good; change in daily routine; felt
sick or ill; and simply forgot (Figure 2). The reason for missing medications that received
the highest response rate during the first 24 weeks was “feeling good" (average=28%), and
among TW24 Responders, the reason with the highest response rate from week 24–48 was
because they “simply forgot” (21%).
Patient Characteristics Associated with Missing PEG and RBV Doses
Baseline to Week 24—Patient characteristics predictive of longitudinally missing doses
of weekly PEG at p<0.20 are shown in bivariate analyses displayed in Table 1. The final
multivariate model, after backwards selection, included: age; race; employment status; and
marital status. Participants who were younger, African-American (AA), unemployed, or
unmarried (i.e., not in a relationship) had higher odds of missing their weekly dose of PEG.
For continuous variables such as age, the unit change represented by the odds ratio is given;
for example, for every 5 year decrease in age, the odds of missing PEG increased by 24% in
the multivariate model (OR=0.76).
Bivariate associations with missing doses of RBV at p<0.20 are shown in Table 2. In the
final multivariate model, after backwards selection, participants had higher odds of missing
more daily doses of RBV if they were younger and AA.
Week 24 to 48—Conditional on being a TW24 Responder, bivariate associations were
conducted and are presented in Table 1. Baseline CES-D was excluded from the initial
multivariate model due to its high correlation with VAS-DEP and its bivariate association
with missing PEG doses not being as strong. The only variable retained in the multivariate
model was VAS-DEP (p=.048). Individuals with higher scores at baseline on the VAS-DEP
were more likely to miss doses of weekly PEG, such that every 1 point increase on the 10-
point depression scale increases the odds of missing PEG by 9%.
Conditional on being a TW24 Responder, bivariate associations with missed doses of RBV
at p<0.20 are shown in Table 2. After backwards selection, insurance and employment status
were significant at 0.05; those employed or with public or no insurance (compared to
private) had greater odds of missing daily RBV doses.
Nonpersistence (i.e., Patient-DrivenTreatment Discontinuations
Of the 401 initial participants, 50 discontinued PEG for various reasons (39 due to
nonpersistence; 8 due to serious adverse events; 3 due to death) during the first 24 weeks of
treatment, resulting in the probability of persisting to 24 weeks of 90.2% (95% CI:
86.8%-92.7%) for PEG. The 39 patients who failed to persist for patient-driven reasons did
so due to intolerance to the medication (41%; n=16); noncompliance with study protocol
(28%; n=11); patient preference (28%; n=11); and other (3%; n=1). Almost identical
numbers were observed for RBV (data not shown).
After Nonresponders were discontinued from therapy, an additional 16 TW24 Responders
discontinued PEG/RBV (13 due to patient-driven nonpersistence; 3 due to serious adverse
events) from week 24 to 48. This resulted in a conditional probability of persisting to week
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48 of 94.5% (95% CI: 90.8%-96.8%) for PEG. The 13 Responders who failed to persist on
treatment did so due to patient preference (46%; n=6); intolerance to medications (31%;
n=4); and noncompliance with study protocol (23%; n=3).
Out of the 66 treatment discontinuations for all causes, 52 (78.8%) were considered patient-
driven nonpersistence events that could be amenable to intervention.
Patient Characteristics Associated with Nonpersistence
Baseline to Week 24—Bivariate associations at p<0.20 with patient-driven
nonpersistence up to week 24 are shown in Table 3. For reasons described above, baseline
VAS-DEP and VAS-ALL were excluded from the initial multivariate model. The final
model, after backwards selection, included: age; education; insurance; and baseline VAS-
HEAD. Participants had a greater risk of being nonpersistent if they were younger, had less
than a high school education, had public or no insurance and had worse headaches at
baseline. Results for RBV nonpersistence were nearly identical since nonpersistence resulted
in discontinuation of both study medications at approximately the same time. For every 5
year decrease in age, the risk of nonpersistence significantly increases by 24% and for every
1 point increase on the 10-point headache scale, the risk of nonpersistence increases 16%.
Week 24 to 48—Characteristics found to be associated at p<0.20 with PEG nonpersistence
in TW24 Responders included: age; race; CES-D; MCS; VAS-DEP; VAS-FAT; and VAS-
IRRIT (Table 3). Multivariate analyses were not conducted due to the small number of
nonpersistent events from 24–48 weeks.
DISCUSSION
Triple therapy will bring new and even more challenging barriers to adherence to HCV
treatment regimens than seen during dual therapy. The current study expands the knowledge
base of adherence-related processes by a) measuring and analyzing missing doses and
nonpersistence (i.e., patient-driven discontinuations) as separate processes; b) using a large
sample size (n=401); c) utilizing MEMs caps, a highly objective, state-of-the-art electronic
monitoring technology to investigate daily dosing; and d) identifying several baseline patient
characteristics associated with missing doses and nonpersistence.
While weekly dosing of PEG injections was excellent (90%) in this study, patients
demonstrated more difficulty adhering to twice daily dosed RBV. Despite intensive
adherence interventions delivered throughout the study, 7% of RBV doses were missed in
the first week of treatment, 15% at week 24, and 25% at week 48. Using MEMS allowed us
to capture a much higher rate of missed RBV doses than has been previously reported by
studies that relied upon self-report which tends to underestimate missed doses (4, 10, 11,
23). These data are concerning given that RBV adherence during the first 24 weeks of
antiviral therapy is critical to viral response (2, 24).
This is the first study to provide insight into why HCV patients miss taking medications.
These data demonstrate that patients miss medications during the first 24 weeks primarily
because they “feel good.” This seems to reflect a deliberate decision on behalf of patient to
consciously refrain from taking their medications when they feel good, and may be
surprising to clinicians who assume that missed doses occur most often due to forgetfulness.
Clinicians should be aware of this phenomenon particularly during the early phase of
treatment. These data highlight the changing etiology of missing doses from early to late
treatment phases, and suggests that drastically different dialog during patient-provider
interactions may be needed to optimize dose-taking behaviors.
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Overall the proportion of patients persisting on treatment, censoring medically-necessary
discontinuations, was quite good. A total of 66 (16.5%) patients were discontinued from
treatment prematurely, 52 (79%) of whom did so due to patient-driven nonpersistence. Most
patients discontinued treatment due to intolerance of treatment-related side effects, while
others failed to persist due to noncompliance with the study protocol or patient preference.
These results have implications for the development of pharmacological and
nonpharmacological interventions to manage side effects. For example, efficacious cognitive
and behavioral interventions that help HIV and cancer patients cope with treatment-related
side effects may provide coping skills to help HCV patients tolerate unpleasant side effects
and persist on therapy (25, 26).
We identified several characteristics of patients for whom additional support will be needed.
Patients who were younger, African-American, unemployed, or those not in a relationship
were at greater risk for missing PEG and/or RBV during the first 24 weeks. Additionally,
younger, less educated patients, with public or no insurance, and more headaches before
treatment were less likely to persist to week 24. The association between lower educational
status and nonpersistence is consistent with a recent study in HCV+ drug users (4). Some of
the characteristics associated with missed doses and nonpersistence are perceived of as
social determinants of health by the Centers for Disease Control (i.e., insurance coverage;
employment; education; access to resources), which have implications for health policy (27).
Clinicians ought to be aware of these correlates of treatment adherence, and future research
could examine more intensive counseling and education, case management, or
multidisciplinary models to improve treatment adherence in at-risk groups.
Historically, there has been reluctance to treat HCV patients with premorbid psychological
disorders owing to safety and adherence concerns (28, 29). However, studies showing an
association between psychological disturbances and premature treatment discontinuations
are equivocal; PEG/RBV registration trials found that depression is a common cause of all-
cause discontinuations (30), while other studies have not (31). Moreover, the few studies
that have investigated the impact of psychological disturbances on missed doses have found
no associations (4, 13, 32). The current study demonstrates that this controversial topic is
even more complex than previously recognized. We found that baseline depressive
symptoms were not associated with missing PEG or RBV or failing to persist during the first
24 weeks, but did predict missing PEG doses from weeks 24 to 48.
Perhaps equally important are the factors that did not engender risk for missed doses or
nonpersistence in this study. No statistically significant gender differences were found for
execution of dosing or persistence. Clinical characteristics such as fibrosis level, history of
drug use, other medications, alcohol use at screening, smoking status, antidepressants, social
support, and quality of life, were not associated with execution of dosing or persistence in
final multivariate models. With regard to symptomatology measured via visual analog
scales, baseline irritability, fatigue, and muscle/joint pain were not threats to dosing or
persistence. Notably, these conclusions need to be interpreted with caution since study
methodology (e.g., exclusion criteria), sample size, and lack of power could have precluded
statistically significant associations from being found.
A few limitations are noted. These findings may not generalize to dissimilar patient
populations (e.g., patients with active drug or alcohol use, comorbid psychiatric illness) or
clinical settings (e.g., non-research clinical practice). In fact, it is likely that these results
reflect the best possible adherence rates for HCV treatment given the sample characteristics
and intensive adherence strategies employed. Clinicians should anticipate even higher rates
of missed doses and nonpersistence under less favorable conditions, and during triple
therapy which requires dosing 3–4 times a day, which has an expected dosing rate of only
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51–65% (3). Another limitation includes low power to detect significant associations in the
survival models for nonpersistence, owing to the small number of events. Finally, MEMs
caps ascertain when the medication vials are opened, but not whether the medication was
actually taken. Despite this limitation, the use of MEMs caps was a significant strength of
the study, overcoming less objective adherence measurements like self-report, which are
subject to both recall and reporting bias.
As previously stated, future research should aim to differentiate between medically-driven
and patient-driven processes that affect adherence to treatment protocols (see Figure 4). We
found that the majority of treatment discontinuations (79%) result from patient-driven
reasons, thereby providing support for properly referring to this process as “nonpersistence”
in order to better align with the broader adherence literature. Medically-driven and patient-
driven discontinuations should be further distinguished from poor execution of dosing and
not combined into one overall adherence variable. Investigations of adherence to HCV
treatment will move the field forward more rapidly if these processes are measured and
analyzed separately, as they are related to different patient characteristics, may have
different clinical consequences, and will require markedly different interventions. The
consequences of nonpersistence and missed doses on viral mutation and treatment response
need to be evaluated. Electronic monitoring devices or other objective measures should be
used to prospectively measure dosing execution in studies where adherence is a primary
outcome. Finally, future studies need to examine the proportion of missed doses during
triple therapy regimens, and ideally would include assessment of dose-timing intervals (i.e.,
every 8 hours) as dose-timing errors have been associated with viral resistance and worse
treatment outcomes in other treatment populations (33).
While the current study was conducted using data collected during the era of dual therapy,
these findings have implications for more complex therapeutic regimens, including
interventions that may optimize execution of dosing and persistence. To improve execution
of dosing, behavioral reminder systems and educational and counseling intervention, which
have been efficacious in HIV adherence research, should be examined (34). Innovative
technology and adherence intervention delivery systems, such as smart-phone technology,
interactive voice response technology, and smart phone video-capture of medication taking
may be useful strategies to investigate (35, 36). In contrast, failing to persist on treatment
could be mitigated through more extensive pre-treatment education, case management,
adjunct pharmacotherapy, and cognitive and behavioral interventions that have proven
efficacious in HIV and cancer care (37, 38).
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a: Average proportion of missed PEG doses over the course of 48 weeks. Each month shown
on the X-axis is the proportion of missed doses for the preceding 4 weeks. PEG dosing
needed to occur 6–8 days after the previous dose to be coded as adherent for each week.
Sample sizes at each time frame are indicated below.
b: Average proportion of missed RBV doses over the course of 48 weeks, shown in weekly
intervals. For each of the preceding 7 days that comprised each week on the X-axis, RBV
dosing had to occur twice within each 24-hour day to be coded as fully adherent or once in
24 hours to be coded as partially adherent for that day. Sample sizes are indicated below.
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Graph shows the most common reasons for missed doses of PEG or RBV (i.e., endorsed by
at least 20% of participants at any one time point) by participants who reported missing any
doses in preceding 4 weeks.
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Conceptual model of HCV adherence-related processes, which differentiates between
various medically-driven and patient-driven factors that can each attenuate overall
adherence to a prescribed HCV treatment regimen.
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